Healthpeak Properties, Inc. DOC
Verdict: Hold. Fair value $20.25 against a price of $16.39 on 6 Jan 2026, 24% above the price.
In plain words
The case for: Narrow competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: GAAP Net Income has declined significantly from $0.51B in 2021 to $0.24B in 2024. During the same.... The company reported a substantial earnings miss for the quarter ending 2025-09-30, with actual EPS....
Main risks
- Collapsing Profitability: Net margin has deteriorated significantly from over 24% (2020-2022) to 8.9% in the latest full year, indicating severe pressure on the bottom line despite revenue growth.
- Extremely High Leverage: Proxied Net Debt/EBITDA of 9.3x is in a high-risk zone. This level of debt magnifies financial risk, especially in a volatile interest rate environment.
- Poor Capital Allocation Returns: ROE (2.9%), ROIC (0.7%), and a proxied 3-year ROIIC (2.1%) are exceptionally low, suggesting that significant recent investments are failing to generate adequate shareholder returns.
- GAAP Net Income has declined significantly from $0.51B in 2021 to $0.24B in 2024. During the same...
- The company reported a substantial earnings miss for the quarter ending 2025-09-30, with actual EPS...
- GAAP Net Income has declined significantly from $0.51B in 2021 to $0.24B in 2024. During the same period, Revenue grew 42% (from $1.90B to $2.70B) and Operating Cash Flow grew 34% (from $0.80B to $1.07B). This indicates that aggressive non-cash charges are severely depressing reported earnings.